AI-generated · cited to primary sources · not investment advice · How we research
Shilpa Medicare
Our verdict on Shilpa Medicare isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Total capex for FY26 was INR 361 crores. Given that H1 FY26 capex was previously guided, the full-year figure indicates robust investment in API, CDMO, and albumin facilities. (1 exceeded across 1 tracked commitment)
“Two NBE programs will be entering in the Phase I studies in FY27.”
The company secured EU approval for the Rotigotine Transdermal Patch ahead of the previously guided Q4 FY26 timeline, receiving it during 3QFY26. (2 exceeded, 3 met across 5 tracked commitments)
“Semaglutide – validation to be completed in 4QFY26, DMF to be readied by 1HFY27”
Management confirmed that the first U.S. NCE program was launched in Q4 FY26 by their big pharma partner. (2 met across 2 tracked commitments)
“GMP facility for ADC is targeted in Q4FY26.”
Management confirmed the successful submission of the Rotigotine Transdermal Patch with the U.S. FDA in Q4 FY26. (1 met across 1 tracked commitment)
“US bioequivalence studies successfully concluded, finalizing our Marketing Application for submission in Q4FY26”
The API segment delivered 11% YoY growth for 3QFY26 and 17% YoY growth for 9MFY26, meeting the double-digit growth target. (3 met across 3 tracked commitments)
“We have added a new oncology block to our existing set up, increasing overall oncology API capacity. The block is expected to get commissioned in FY27.”
See the full cited Management analysis of Shilpa Medicare
How durable is the business?
Formulation revenue reached INR 98 crores, with growth driven by European and Rest of World (ROW) markets. The company achieved a milestone with the approval of its first New Chemical Entity (NCE), Nor-Ursodeoxycholic acid. (5 expanding across 1 engine)
“Formulation revenue for the quarter were INR205 crores, growing at 54% year-on-year”
The company is strengthening its technological moat by advancing its Biologics and ADC (Antibody-Drug Conjugate) platforms, with its first ADC biosimilar expected to enter human studies in FY27. (2 expanding)
“And for the full year '26, we have had historic revenue number, delivering INR1,549 crores, growing at 18%... yearly EBITDA margin of 29%”
Regulatory standing improved as the company received an Establishment Inspection Report (EIR) from the U.S. FDA for its transdermal patch manufacturing facility, opening the U.S. market for this niche category. (2 expanding)
“I'm happy to inform everyone that in the current quarter, we have received EIR from U.S. FDA for our transdermal patch manufacturing facility, which will open opportunities in the U.S. market also for our transdermal patch facility.”
The company's technological moat is strengthening as it moves into first-of-its-kind facilities in India, specifically for Antibody Drug Conjugates (ADCs) and recombinant Albumin. They are also entering the high-barrier GLP-1 (peptide) market. (1 expanding)
“GMP facility for our ADC manufacturing, we are planning to commission in Q4 FY '26. It will be first of its kind ADC manufacturing facility in India with integrated payload linker and conjugation facility.”
The API segment achieved its highest-ever Q1 performance, driven by portfolio rationalization and increased offtake from expanded capacities in products like Tranexamic acid and Ursodeoxycholic acid. (5 expanding across 1 engine)
“Our API business clocked a revenue of INR259 crores for the quarter... growing at 16%, both on a quarterly as well as yearly basis.”
See the full cited Business Model analysis of Shilpa Medicare
Where does growth come from?
Biologics revenue shows massive sequential acceleration, jumping from INR 10 Cr to INR 37 Cr (on a specific segment basis) or INR 73 Cr (on a consolidated biosimilars business basis) depending on the reporting lens used in the call. (5 accelerating across 5 signals, 2 leading indicators)
“For the full year, EBITDA was at INR445 crores... with yearly EBITDA margin of 29%, an, ~3% year-on-year improvement. This improvement in EBITDA was largely driven by increased revenue from key verticals driving positive operating leverage.”
The company faces a potential growth constraint due to an ongoing US FDA audit at its Jadcherla facility, which has led to observations that must be cleared before new high-value products can be approved for the US market.
“It's just that the facility when the audit happened, the FDA has given some observations. We have done the compliance. And now we are again waiting for the reaudit of that... there are certain tentative approvals pending because of this audit issue.”
The pipeline is accelerating with concrete regulatory milestones achieved, including EMA authorization for Rotigotine and US FDA suitability petition approval for Tadalafil ODF. (1 accelerating across 1 signal)
“Received final marketing authorization from EMA, gearing up for 1HFY27 launch... The US FDA approved our suitability petition for Tadalafil ODF”
EBITDA margins are accelerating, reaching 28% in 3QFY26 (up 200 bps YoY) and 29% for 9MFY26 (up 300 bps YoY), driven by a shift toward higher-margin complex products. (1 accelerating, 1 steady across 2 signals)
“EBITDA came in at INR 323crs, growing 26% YoY; EBITDA Margins improved by ~300 bps to 29% YoY”
The company is accelerating its API growth through newly increased capacities for key products like UDCA and Azacitidine, with a new dedicated block for OLC expected to commercialize in FY26. (3 accelerating, 2 steady across 5 signals)
“Newly increased capacities for key products viz. UDCA, Tranexamic Acid, Azacitidine, Palbociclib and Nilotinib to contribute materially in FY26... New dedicated block for OLC expected to be commercialized in FY26”
See the full cited Future Growth analysis of Shilpa Medicare
What could break the thesis?
Management reports that Nilotinib is currently 'doing reasonably good' with a strong order book, but the long-term risk of generic entry in FY28 remains a structural concern that hasn't changed. (2 stable, 1 intensifying, 1 high-severity)
“we are expecting some generic competition to come in current financial year... The more impact will be there for the FY28. So to answer you, that is what is the answer for Nilotinib.”
The risk is easing as the company received an Establishment Inspection Report (EIR) from the U.S. FDA for its transdermal patch manufacturing facility, which is a critical step toward opening U.S. market opportunities. (4 easing, 1 stable, 1 high-severity)
“It's just that the facility when the audit happened, the FDA has given some observations. We have done the compliance. And now we are again waiting for the reaudit of that... our major focus on U.S. will be from third-party CMOs.”
The risk is INTENSIFYING as management explicitly noted that prices for raw materials and solvents have 'gone up significantly,' even though availability is stable. (1 intensifying, 1 emerging, 3 easing)
“On the debt front, our net debt for the year increased to INR 613 crores from INR 550 crores in the previous year”
The risk is INTENSIFYING as the IMPD submission has been delayed from Q4 to the first half of FY27 to accommodate testing from a new facility. (1 intensifying, 1 easing, 3 stable)
“for Aflibercept, currently, there is no plan of going into Europe market because it's a very long study and very costly study, and we feel that we are late for Europe market.”
Margins have significantly improved to 76% (up 700 bps YoY) due to a better product mix and licensing income, suggesting that input cost pressures are currently being offset by high-value launches. (5 easing)
“Our gross margins for the quarter were at 76%, an improvement of 700 basis points compared to last year. And this improvement was mainly driven by a better product mix.”
See the full cited Risk analysis of Shilpa Medicare
Read the full thesis on Shilpa Medicare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.